@article{KrokeSchmidtAminietal.2022,
  author    = {Kroke, Anja and Schmidt, Annemarie and Amini, Anna M. and Kalotai, Nicole and Lehmann, Andreas and Haardt, Julia and Bauer, J{\"u}rgen M. and Bischoff-Ferrari, Heike A. and Boeing, Heiner and Egert, Sarah and Ellinger, Sabine and K{\"u}hn, Tilman and Louis, Sandrine and Lorkowski, Stefan and Nimptsch, Katharina and Remer, Thomas and Schulze, Matthias B. and Siener, Roswitha and Stangl, Gabriele and Volkert, Dorothee and Zittermann, Armin and Buyken, Anette E. and Watzl, Bernhard and Schwingshackl, Lukas},
  title     = {Dietary protein intake and health-related outcomes: a methodological protocol for the evidence evaluation and the outline of an evidence to decision framework underlying the evidence-based guideline of the German Nutrition Society},
  series = {European journal of nutrition},
  volume    = {61},
  journal   = {European journal of nutrition},
  number    = {4},
  publisher = {Springer Nature},
  address   = {Heidelberg},
  organization    = {German Nutr Soc},
  issn      = {1436-6207},
  doi       = {10.1007/s00394-021-02789-5},
  pages     = {2091 -- 2101},
  year      = {2022},
  abstract  = {Purpose: The present work aimed to delineate (i) a revised protocol according to recent methodological developments in evidence generation, to (ii) describe its interpretation, the assessment of the overall certainty of evidence and to (iii) outline an Evidence to Decision framework for deriving an evidence-based guideline on quantitative and qualitative aspects of dietary protein intake. Methods A methodological protocol to systematically investigate the association between dietary protein intake and several health outcomes and for deriving dietary protein intake recommendations for the primary prevention of various non-communicable diseases in the general adult population was developed. Results The developed methodological protocol relies on umbrella reviews including systematic reviews with or without meta-analyses. Systematic literature searches in three databases will be performed for each health-related outcome. The methodological quality of all selected systematic reviews will be evaluated using a modified version of AMSTAR 2, and the outcome-specific certainty of evidence for systematic reviews with or without meta-analysis will be assessed with NutriGrade. The general outline of the Evidence to Decision framework foresees that recommendations in the derived guideline will be given based on the overall certainty of evidence as well as on additional criteria such as sustainability. Conclusion The methodological protocol permits a systematic evaluation of published systematic reviews on dietary protein intake and its association with selected health-related outcomes. An Evidence to Decision framework will be the basis for the overall conclusions and the resulting recommendations for dietary protein intake.},
  language  = {en}
}
@article{BirukovGlintborgSchulzeetal.2022,
  author    = {Birukov, Anna and Glintborg, Dorte and Schulze, Matthias B. and Jensen, Tina K. and Kuxhaus, Olga and Andersen, Louise B. and Kr{\"a}ker, Kristin and Polemiti, Elli and Jensen, Boye L. and J{\o}rgensen, Jan S. and Dechend, Ralf and Andersen, Marianne S.},
  title     = {Elevated blood pressure in pregnant women with gestational diabetes according to the WHO criteria: importance of overweight},
  series = {Journal of hypertension},
  volume    = {40},
  journal   = {Journal of hypertension},
  number    = {8},
  publisher = {Lippincott Williams \& Wilkins},
  address   = {Philadelphia},
  issn      = {0263-6352},
  doi       = {10.1097/HJH.0000000000003196},
  pages     = {1614 -- 1623},
  year      = {2022},
  abstract  = {Objective: Hypertension before and during early pregnancy has been associated with an increased risk of gestational diabetes mellitus (GDM) in retrospective analyses. We aimed to investigate the prospective blood pressure trackings in a population-based cohort of pregnant women, who were stratified according to their metabolic status in early third trimester. Methods: We recorded blood pressure longitudinally during pregnancy in 1230 women from the Odense Child Cohort, Denmark. Fasting glucose and insulin were measured at gestational weeks 28-30. Metabolic status was evaluated according to the WHO 2013 threshold for GDM (GDM-WHO: fasting plasma glucose >= 5.1 mmol/l), insulin and homeostatic model assessment of insulin resistance (HOMA-IR). Relationships between metabolic status in third trimester and blood pressure trajectories were evaluated with adjusted linear mixed models. Trajectory was defined as blood pressure records in pregnancy per 4 weeks interval. Results: Prevalence of GDM-WHO was 40\% (498/1230). GDM-WHO was associated with 1.46 (0.22-2.70) mmHg higher SBP and 1.04 (0.07-2.01) mmHg higher DBP trajectories in the overall cohort. The associations were driven by differences in the overweight group, with 3.14 (1.05-5.25) mmHg higher SBP and 1.94 (0.42-3.47) mmHg higher DBP per 4 weeks in women with GDM-WHO compared with women without GDM-WHO. GDM-WHO was not associated with blood pressure in women with normal weight. Blood pressure trajectories were elevated across quartiles of insulin resistance. Conclusion: GDM-WHO is associated with higher blood pressure in pregnancy, and there appears to be a stronger effect in overweight women.},
  language  = {en}
}
@article{WittenbecherCuadratJohnstonetal.2022,
  author    = {Wittenbecher, Clemens and Cuadrat, Rafael and Johnston, Luke and Eichelmann, Fabian and J{\"a}ger, Susanne and Kuxhaus, Olga and Prada, Marcela and Del Greco, Fabiola M. and Hicks, Andrew A. and Hoffman, Per and Krumsiek, Jan and Hu, Frank B. and Schulze, Matthias B.},
  title     = {Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology},
  series = {Nature communications},
  volume    = {13},
  journal   = {Nature communications},
  publisher = {Nature Research},
  address   = {Berlin},
  issn      = {2041-1723},
  doi       = {10.1038/s41467-022-28496-1},
  pages     = {13},
  year      = {2022},
  abstract  = {Metabolic alterations precede cardiometabolic disease onset. Here we present ceramide- and dihydroceramide-profiling data from a nested case-cohort (type 2 diabetes [T2D, n = 775]; cardiovascular disease [CVD, n = 551]; random subcohort [n = 1137]) in the prospective EPIC-Potsdam study. We apply the novel NetCoupler-algorithm to link a data-driven (dihydro)ceramide network to T2D and CVD risk. Controlling for confounding by other (dihydro)ceramides, ceramides C18:0 and C22:0 and dihydroceramides C20:0 and C22:2 are associated with higher and ceramide C20:0 and dihydroceramide C26:1 with lower T2D risk. Ceramide C16:0 and dihydroceramide C22:2 are associated with higher CVD risk. Genome-wide association studies and Mendelian randomization analyses support a role of ceramide C22:0 in T2D etiology. Our results also suggest that (dh)ceramides partly mediate the putative adverse effect of high red meat consumption and benefits of coffee consumption on T2D risk. Thus, (dihydro)ceramides may play a critical role in linking genetic predisposition and dietary habits to cardiometabolic disease risk.},
  language  = {en}
}